BNTX BioNTech SE
Healthcare$92.25+0.12%ClosedMarket Cap: $23.33B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.08
P/S
7.20
EV/EBITDA
-14.97
DCF Value
$49.19
FCF Yield
3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.6%
Operating Margin
-52.1%
Net Margin
-44.7%
ROE
-6.7%
ROA
-5.9%
ROIC
-7.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $120.0M | -63.2% | $-672.0M | $-540.6M | $— | — |
| Q4 null | $898.9M | 63.3% | $-230.6M | $-302.1M | $— | — |
| FY null | $2.76B | 77.6% | $-623.9M | $-1.09B | $— | — |
| Q3 null | $1.52B | 90.2% | $-46.9M | $-28.7M | $— | — |
| Q2 null | $260.8M | 70.7% | $-501.1M | $-386.6M | $— | — |
| Q1 null | $182.8M | 54.2% | $-534.1M | $-415.8M | $— | — |
| Q4 null | $1.19B | 79.5% | $148.6M | $259.5M | $— | — |
| FY null | $2.75B | 80.3% | $-1.31B | $-665.3M | $— | — |
| Q3 null | $1.24B | 85.6% | $10.5M | $198.1M | $— | — |
| Q2 null | $128.7M | 53.5% | $-966.2M | $-807.8M | $— | — |
| Q1 null | $187.6M | 68.5% | $-507.2M | $-315.1M | $— | — |
| Q4 2023 | $1.48B | 87.9% | $526.2M | $457.9M | $1.84 | — |